How much immunosuppression do we need?

Abstract

It is frustrating that after more than 3 decades, we still don't know the optimal graft-versus-host disease (GVHD) prophylaxis regimen. In this issue of Blood, Kanakry and coworkers report on posttransplantation cyclophosphamide (PTCy) as a single-agent GVHD prophylaxis in HLA-matched bone marrow transplantation (BMT) and include an analysis of how much additional immunosuppressive therapy the patients eventually required.1